Finance

Beta
Lists
688105:SHA
Nanjing Vazyme Biotech Co Ltd
CNÂ¥13.61
+0.22%
(+0.030) 1D
Jun 10, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688105...
Open
CNÂ¥13.45
High
CNÂ¥13.70
Low
CNÂ¥13.09
Mkt. cap
7.02B
Avg. vol.
3.52M
Volume
3.26M
Dividend
2.83%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jun 3, 2026
52-wk high
CNÂ¥20.59
52-wk low
CNÂ¥12.89
EPS
-CNÂ¥0.03
No. of employees
3K
Open
CNÂ¥13.45
High
CNÂ¥13.70
Low
CNÂ¥13.09
Mkt. cap
7.02B
Avg. vol.
3.52M
Volume
3.26M
Dividend
2.83%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jun 3, 2026
52-wk high
CNÂ¥20.59
52-wk low
CNÂ¥12.89
EPS
-CNÂ¥0.03
No. of employees
3K
News stories
From sources across the web
About Nanjing Vazyme Biotech Co Ltd
CEO-
Employees3K
FoundedMar 16, 2012
Headquarters-
SectorBiotechnology
Websitevazyme.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
321.24M
346.18M
425.48M
320.65M
Cost of goods sold
109.41M
93.31M
167.76M
92.87M
Cost of revenue
109.41M
93.31M
167.76M
92.87M
Research and development expenses
64.68M
71.34M
78.18M
67.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
167.32M
191.43M
208.11M
164.74M
Operating expense
237.49M
245.18M
323.26M
235.80M
Total operating expenses
346.90M
338.49M
491.02M
328.67M
Operating income
-25.66M
7.70M
-65.54M
-8.02M
Other non operating income
-4.32M
2.46M
-4.62M
132.05K
EBT including unusual items
-5.38M
-6.90M
-21.16M
-4.00M
EBT excluding unusual items
-23.56M
5.30M
-64.66M
-8.78M
Income tax expense
-5.55M
-8.58M
5.06M
-5.99M
Effective tax rate
103.28%
124.31%
-23.92%
149.67%
Other operating expenses
774.40K
-13.76M
20.96M
3.29M
Net income
1.22M
3.49M
-23.23M
4.18M
Net profit margin
0.38%
1.01%
-5.46%
1.30%
Earnings per share
-
-
-
-
Interest and investment income
6.54M
7.60M
6.73M
5.27M
Interest expense
-6.75M
-5.82M
-4.61M
-6.16M
Net interest expenses
-214.70K
1.79M
2.12M
-885.26K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.10M
31.56M
-42.56M
14.95M
Gain or loss from assets sale
-15.58K
15.58K
293.68K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer